Pipeline Strategy and Progress
Globally competitive Pipeline Globally competitive Pipeline

With a strategic emphasis on oncology, we have identified seven drug candidates and developed a robust pipeline of product candidates through collaborations and internal discoveries, including small molecules, monoclonal/bifunctional antibodies and oncolytic virus.


Currently, we have three programs that are being investigated in clinical trials: With fast track designation from FDA, AN2025(buparlisib) is expected to be the first-in-class drug for treating recurrent or static HNSCC (Phase III multi-center clinical trial). AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. AN4005, our clinically most advanced drug candidate from in-house discovery, is a potential first-in-class, orally available, small-molecule PD-L1 inhibitor.


We continue actively advancing four in-house preclinical programs considered to have high global commercial viability, including AN3025, an immune-stimulatory anti-human TNFR2 antibody; AN1025, an oral small molecule of β-catenin degrader; AN8025, a multifunctional antibody as T cell and APC modulator, and AN6025, an oral small molecule HPK1 inhibitor. 


We are working on discovering combination solutions while developing unique cocktail therapy, aiming to bring effective treatment for patients.  

Discovery
IND Enabling
Phase Ia
Phase Ib
Phase II
Phase III
AN2025
buparlisib
HNSCC 2/3L (+paclitaxel)
Global
PIK3CA mutant solid tumors 2/3L (+Tecentriq®+AN0025)
Global
AN0025
palupiprant
TNBC, NSCLC, bladder cancer, microsatellite stable CRC and cervical cancer 2/3L (+Keytruda®)
Global (Excl. Japan, South Korea and partial SEA countries)
AN4005
Advanced tumors
Global (Excl. greater China)
AN3025
Advanced tumors
Global (Excl. greater China)
AN1025
Advanced tumors
Global
AN8025
Advanced tumors
Global
AN6025
Advanced tumors
Global